Immatics US, Inc. was launched in June 2015 by Immatics GmbH and the University of Texas MD Anderson Cancer Center.
The Company is developing Adoptive Cell Therapies (ACT) approaches based on Immatics’ unrivalled cancer target discovery capabilities and MD Anderson’s world-leading clinical oncology and cell therapy expertise.
Immatics US, Inc. will focus on three adoptive cell therapy development approaches to treat tumors:
- ACTolog™ uses the cancer patient’s own (autologous) T cells specifically recognizing Immatics’ XPRESIDENT® targets. Then we cultivate large numbers of these cancer-specific T cells outside the body before being reinfused back into the patient.
- ACTengine™ involves genetically engineering a patient’s own T cells to express novel T-cell receptors which are specific to Immatics’ XPRESIDENT® targets. Such “reprogrammed” T cells are then cultivated in large numbers outside the body before being reinfused into the patient.
- ACTallo™ is our next-generation approach. It works the same way as ACTengine™ but does not reprogram the patient’s own cells but uses allogenic gamma- delta T cells (non-patient specific) which means they can be used “off-the-shelf” for the quicker treatment of any patient with that particular cancer.
All three ACT approaches have complementary properties regarding efficacy, safety and ease/duration of manufacturing. The first ACT programs will target cancers with high medical need, are expected to enter the clinic in 2016.
To execute its business plan, Immatics US, Inc. has will receive over $40 million of committed funding over the next years from the parent company. In addition, Immatics US, Inc. has been awarded a $19. 7 million grant from the Cancer Prevention Research Institute of Texas (CPRIT) in 2015.
Immatics US, Inc. is based in Houston, Texas, USA close to the MD Anderson Cancer Center.